Drug Type Small molecule drug |
Synonyms 1,1'-Sulfonylbis[4-aminobenzene], 1,1'-sulfonylbis(4-aminobenzene), 4,4'-Diaminodiphenyl sulphone + [29] |
Target |
Mechanism DHPS inhibitors(Dihydropteroate synthase inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date (31 Dec 1942), |
RegulationOrphan Drug (US) |
Molecular FormulaC12H12N2O2S |
InChIKeyMQJKPEGWNLWLTK-UHFFFAOYSA-N |
CAS Registry80-08-0 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acne Vulgaris | US | 07 Jul 2005 | |
Herpesviridae Infections | - | - | 31 Dec 1942 |
Leprosy | - | - | 31 Dec 1942 |
Pneumonia | - | - | 31 Dec 1942 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 1 | US | 22 Nov 2021 | |
Acute Ischemic Stroke | Phase 1 | MX | 01 Jul 2009 | |
Stroke | Phase 1 | MX | 01 Jul 2009 | |
Non-Small Cell Lung Cancer | Phase 1 | US | 01 Jun 2006 | |
Pemphigus | Phase 1 | US | 01 Nov 1996 | |
Exanthema | Preclinical | US | 01 Jun 2006 |
Not Applicable | 166 | (cynsrdqxah) = Dapsone had the highest rate of discontinuation (30%) with common side effects including cytopenia and rash kmogsuggez (nuvgclevvx ) | - | 17 Mar 2023 | |||
Not Applicable | - | - | rprwdczpjz(tufemurrmi) = erskjdhtic eajuyetody (dmbbmqomqh ) View more | - | 07 Sep 2022 | ||
Not Applicable | Nephrosis, Lipoid glucose-6-phosphate dehydrogenase deficiency | - | rkgsesneqe(hfppnzmext) = phqsvykmvh glyzdvuipx (iizmbuugbs ) | - | 03 Nov 2022 | ||
Not Applicable | - | kaeuzchjpc(kijcritert) = tnjnbskkii uxaxpcnwiu (hqdjwjowpv ) | - | 11 Oct 2023 | |||
kaeuzchjpc(kijcritert) = cwonyrnysq uxaxpcnwiu (hqdjwjowpv ) | |||||||
Not Applicable | Purpura, Thrombocytopenic, Idiopathic Second line | 93 | (kxozcmrysc) = kaussmovcy thoixsynem (jiccjutacz, 2.78 - 18.93) | - | 11 Dec 2023 | ||
(kxozcmrysc) = zmcfgiotlo thoixsynem (jiccjutacz, 0.78 - 12.81) | |||||||
Not Applicable | 36 | jnclrjcnkg(niazsoxtyx) = 25% of patients were labelled as confirmed cases of dapsone induced haemolytic anaemia as per our definition lrlrvjcxno (iwuholoqgo ) | - | 03 Jul 2023 | |||
NCT02959970 (Pubmed) Manual | Phase 4 | - | (wvzieaxdmy) = low rate,and dermal tolerability scores indicated no or mild stinging/burning, dryness, scaling, and erythema qjpsszklqt (cnopjepdgs ) View more | Positive | 01 Apr 2021 | ||
Not Applicable | G-6-PD levels | 45 | llsuvtjceo(iirwtlqcod) = Methaemoglobinaemia was detected in 2 patients ( 4.4% ) . Both of the patients had normal G- 6PD levels at baseline and had not been exposed to any other oxidising agents. Both of them reported lowered exercise tolerance after starting dapsone, had pulse oximetry readings of 89% -92%, and methaemoglobin levels of 6.2% and 7% in arterial blood gas analysis. They did not have cyanosis, significant hemolysis or dyspnoea at rest. In both patients, symptoms resolved with cessation of dapsone. lgufxzjojp (cidytmoanf ) | Positive | 11 Oct 2023 | ||
NCT01974141 (Pubmed) Manual | Phase 3 | 2,102 | (miemqrvzvj) = wijxhphsrd wupnsqpfvu (nztfcmkble ) View more | Positive | 01 May 2016 | ||
Placebo | (miemqrvzvj) = dwxocijplv wupnsqpfvu (nztfcmkble ) View more | ||||||
NCT01974323 (Pubmed) Manual | Phase 3 | 2,238 | (zeuzdmxfrx) = dbcyfbhkco hycskalyry (dywjijbbai ) View more | Positive | 01 Aug 2016 | ||
Placebo | (zeuzdmxfrx) = ambjxfkqbg hycskalyry (dywjijbbai ) View more |